Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease
Intensification of the infliximab (IFX) regimen is recommended if the treatment effect is inadequate. The rationale for this is not well defined as the underlying mechanisms vary.
